Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3 clinical trial trial evaluating the safety and efficacy of dronabinol (oral) for the treatment of obstructive sleep apnea

Next Previous
Trial Profile

A Phase 3 clinical trial trial evaluating the safety and efficacy of dronabinol (oral) for the treatment of obstructive sleep apnea

Status: Planning
Phase of Trial: Phase III

Latest Information Update: 10 Aug 2020

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dronabinol (Primary)
  • Indications Sleep apnoea syndrome
  • Focus Registrational; Therapeutic Use
  • Sponsors RespireRx Pharmaceuticals

    • Most Recent Events

    • 03 Aug 2020 According to a RespireRx Pharmaceuticals media release, pending the completion of a new formulation of dronabinol and an intended pre-IND meeting with the FDA, the company believes that it will be able to commence a pharmacokinetic study for the new formulation followed by phase III study for the treatment of OSA.
    • 03 Jan 2019 RespireRx planning to proceed directly to a Phase 3 pivotal trial using the currently available dronabinol formulation (2.5, 5 and 10 mg gel caps)
    • 19 Jun 2018 According to a RespireRx Pharmaceuticals media release, subjects to the outcome of an intended meeting with the FDA, the company will be able to commence this trial.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top